These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 22615459)

  • 21. Detection of clonally expanded salivary gland lymphocytes in Sjögren's syndrome.
    Freimark B; Fantozzi R; Bone R; Bordin G; Fox R
    Arthritis Rheum; 1989 Jul; 32(7):859-69. PubMed ID: 2546568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunohistochemical study of inflammatory infiltrates in minor salivary glands in Sjögren's syndrome and other autoimmune diseases].
    Tomás S; Coll J; Reth P; Corominas JM
    Med Clin (Barc); 1998 Nov; 111(18):681-6. PubMed ID: 9887430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased interleukin (IL)-7Rα expression in salivary glands of patients with primary Sjogren's syndrome is restricted to T cells and correlates with IL-7 expression, lymphocyte numbers and activity.
    Bikker A; Kruize AA; Wenting M; Versnel MA; Bijlsma JW; Lafeber FP; van Roon JA
    Ann Rheum Dis; 2012 Jun; 71(6):1027-33. PubMed ID: 22312161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome.
    Hansen A; Odendahl M; Reiter K; Jacobi AM; Feist E; Scholze J; Burmester GR; Lipsky PE; Dörner T
    Arthritis Rheum; 2002 Aug; 46(8):2160-71. PubMed ID: 12209521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IgA rheumatoid factor in primary Sjogren's syndrome.
    Peen E; Mellbye OJ; Haga HJ
    Scand J Rheumatol; 2009; 38(1):46-9. PubMed ID: 18942022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma.
    Pijpe J; van Imhoff GW; Vissink A; van der Wal JE; Kluin PM; Spijkervet FK; Kallenberg CG; Bootsma H
    Ann Rheum Dis; 2005 Jun; 64(6):958-60. PubMed ID: 15576414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B Cell Depletion Therapy Normalizes Circulating Follicular Th Cells in Primary Sjögren Syndrome.
    Verstappen GM; Kroese FG; Meiners PM; Corneth OB; Huitema MG; Haacke EA; van der Vegt B; Arends S; Vissink A; Bootsma H; Abdulahad WH
    J Rheumatol; 2017 Jan; 44(1):49-58. PubMed ID: 28042126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome.
    Lavie F; Miceli-Richard C; Quillard J; Roux S; Leclerc P; Mariette X
    J Pathol; 2004 Apr; 202(4):496-502. PubMed ID: 15095277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T regulatory cells are markedly diminished in diseased salivary glands of patients with primary Sjögren's syndrome.
    Li X; Li X; Qian L; Wang G; Zhang H; Wang X; Chen K; Zhai Z; Li Q; Wang Y; Harris DC
    J Rheumatol; 2007 Dec; 34(12):2438-45. PubMed ID: 18050367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: a double-blind, placebo-controlled study.
    Abdulahad WH; Meijer JM; Kroese FG; Meiners PM; Vissink A; Spijkervet FK; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2011 Apr; 63(4):1116-23. PubMed ID: 21225693
    [No Abstract]   [Full Text] [Related]  

  • 31. The numbers of Foxp3 + Treg cells are positively correlated with higher grade of infiltration at the salivary glands in primary Sjogren's syndrome.
    Sarigul M; Yazisiz V; Bassorgun CI; Ulker M; Avci AB; Erbasan F; Gelen T; Gorczynski RM; Terzioglu E
    Lupus; 2010 Feb; 19(2):138-45. PubMed ID: 19952070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome.
    Pollard RP; Abdulahad WH; Bootsma H; Meiners PM; Spijkervet FK; Huitema MG; Burgerhof JG; Vissink A; Kroese FG
    Ann Rheum Dis; 2013 Dec; 72(12):2048-50. PubMed ID: 23864239
    [No Abstract]   [Full Text] [Related]  

  • 33. [Rituximab therapy for systemic manifestations and MALT lymphomas of the parotid gland in Sjögren's disease: preliminary data].
    Logvinenko OA; Vasil'ev VI; Sedyshev SKh; Safonova TN; Rodionova EB; Kokosadze NV; Aleksandrova EN; Cherkasova MV; Radenska-Lopovok SG; Nasonov EL
    Ter Arkh; 2012; 84(12):88-96. PubMed ID: 23479998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
    Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R
    Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren's syndrome.
    Risselada AP; Kruize AA; Goldschmeding R; Lafeber FP; Bijlsma JW; van Roon JA
    Ann Rheum Dis; 2014 Aug; 73(8):1537-40. PubMed ID: 24525912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sjögren's syndrome.
    Dörner T; Lipsky PE
    Arthritis Res; 2002; 4(6):360-71. PubMed ID: 12453312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
    Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X
    Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren's Syndrome.
    Jousse-Joulin S; Devauchelle-Pensec V; Cornec D; Marhadour T; Bressollette L; Gestin S; Pers JO; Nowak E; Saraux A
    Arthritis Rheumatol; 2015 Jun; 67(6):1623-8. PubMed ID: 25708147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete remission of protein-losing gastroenteropathy associated with Sjögren's syndrome by B cell-targeted therapy with rituximab.
    Uraoka Y; Tanigawa T; Watanabe K; Machida H; Okazaki H; Yamagami H; Watanabe K; Tominaga K; Watanabe T; Fujiwara Y; Arakawa T
    Am J Gastroenterol; 2012 Aug; 107(8):1266-8. PubMed ID: 22859008
    [No Abstract]   [Full Text] [Related]  

  • 40. [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?].
    Atzeni F; Sarzi-Puttini P
    Reumatismo; 2010; 62(2):87-8. PubMed ID: 20657883
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.